PET predicts GI cancer's early response to chemo

Article

F-18 FDG-PET can tell which patients will respond to neoadjuvant chemotherapy for advanced adenocarcinoma of the esophagogastric junction only two weeks after they begin treatment, according to a study released at the 2007 SNM meeting.

F-18 FDG-PET can tell which patients will respond to neoadjuvant chemotherapy for advanced adenocarcinoma of the esophagogastric junction only two weeks after they begin treatment, according to a study released at the 2007 SNM meeting.

German investigators evaluated 110 patients who underwent FDG-PET to assess response to chemotherapy. Researchers defined as responders patients with 35% or greater decrease in tumor standardized uptake value after two weeks of treatment. Responders went on chemotherapy for 12 weeks before surgery, while nonresponders discontinued treatment and proceeded to surgery right away.

Researchers found statistically significant evidence (p < .002) that responders survived about twice as long as nonresponders during a median follow-up of 2.3 years.

Recent Videos
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Related Content
© 2025 MJH Life Sciences

All rights reserved.